NRGN and Alzheimer disease: Janelidze et al. (2015), measured CSF neurogranin and YKL-40 levels in a cohort of 338 individuals including cognitively healthy controls and patients with sporadic MCI, MCI which later developed AD, PD, DLB, VaD, and FTD patients.